So digging into what candid has said earlier, the 9.7M options are held by 7 individuals and further more 3.5M are held by the CEO who has not sold a single share since joining. None of the management team have sold shares, I think it's highly unlikely there will be any conversion of these options based on the current SP performance and market depth.
Considering the expiry of June 2022, management still have nearly a year to bring interest back into company.
Elective surgery worldwide has taken a hit due to the pandemic which has obviously impacted OSX.
I still think there is allot happening to bring upside from current levels - $35M ex $~6M cash as a revenue generating Biotech, I think this is being heavily over sold. EV of <$30M makes this very attractive when compared to other biotechs.
Add to My Watchlist
What is My Watchlist?
